Patrys Limited · ASX:PAB
Patrys — ShareCafe Small Cap "Hidden Gems" Webinar (November 2022)
19 slides from Patrys's conference presentation, Nov 24, 2022
Slide 1: Investor Webinar Presentation (ASX & Media Release)
ASX & Media Release Investor Webinar Presentation For personal use only Melbourne, Australia; 24 November 2022: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held tomorrow, Friday 25th of Novembe
Slide 2: About Patrys Limited
About Patrys Limited Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. More information can be found at www.patrys.com. For personal use only About Patrys’ deoxymab 3E10
Slide 3: ShareCafe Presentation
For personal use only ShareCafe Presentation Dr James Campbell CEO and MD 25 November 2022
Slide 4: Safe harbour statement
Safe harbour statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 5: Investment summary
Investment summary For personal use only Patrys’ deoxymab technology platform provides new ways for using antibodies to treat cancer: • Block repair of damaged DNA • Cross the blood brain barrier • Can be used alone or in combination with other therapies Deoxymab antibodies can be used as targeting
Slide 6: Company snapshot
Company snapshot For personal use only 12 month share price performance Shares 2.1B Market cap¹ A$41M Cash² A$7.2M HQ Melbourne Charmaine Gittleson (Chair) James Campbell (CEO & MD) Board Pamela Klein (NED) Suzy Jones (NED) Mike Stork (NED) Price¹ $0.020 12 mth high - low $0.045 - $0.018 Dr Dax Marc
Slide 7: Board of Directors
Board of Directors For personal use only Dr Charmaine Gittleson Dr Pamela M. Klein • Former Chief Medical Officer of CSL Limited • Former VP, Development at Genentech • Global expertise in drug development, • Board member of Argenx (Euronext & Nasdaq: ARGX) clinical development, regulatory strategy
Slide 8: Overview Technology
For personal use only Overview Technology
Slide 9: Novel anti-cancer therapeutic antibody
Novel anti-cancer therapeutic antibody For personal use only Deoxymabs bind to DNA and have a unique combination of properties: • Cancer seeking: tumours release DNA which attracts deoxymabs • Cell penetrating: able to get into cells and the cell nucleus • Block DNA damage repair (DDR): stops cancer
Slide 10: Deoxymabs: multiple therapeutic approaches
Deoxymabs: multiple therapeutic approaches For personal use only Single Agent Combination Therapies Targeted Therapies • Active against cancers with defects • Radiation and many chemo drugs work • Deoxymabs can be used to in their DNA damage repair systems by damaging DNA target delivery of payloads
Slide 11: PAT-DX1 - anticancer activity demonstrated in multiple models
PAT-DX1 - anticancer activity demonstrated in multiple models For personal use only As a single agent Breast Cancer Brain Metastases • 47% improvement in survival in animal model of glioblastoma • Most common primary brain cancer (23,000 new cases in US pa) In combination with radiation • 25% improv
Slide 12: Commercial Landscape
For personal use only Landscape Commercial
Slide 13: Biologics typically transact earlier and at higher valuations than small molecules
Biologics typically transact earlier and at higher valuations than small molecules For personal use only The value of Patrys’ novel therapy is underpinned by potential for multiple applications to achieve better patient outcomes Source: GlobalData 1.Small molecules and biologics transactions between
Slide 14: Deal landscape - recent example
Deal landscape - recent example For personal use only November 1, 2022 • Exelixis (NASDAQ, US$5.3B) and Cybrexa Therapeutics (US, private) establish exclusive collaboration giving Exelixis the Right to Acquire CBX- 12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan • US$60 million up
Slide 15: Looking Ahead
For personal use only Ahead Looking
Slide 16: PAT-DX1 clinical trial preparation for H2 2023
PAT-DX1 clinical trial preparation for H2 2023 For personal use only • Cell line for manufacturing selected in 2021 • Engineering run successfully completed in July 2022 • No major concerns identified in non-GLP toxicology in rodents and NHPs • GLP toxicology studies (rodents, NHPs) have commenced •
Slide 17: PAT-DX3 development path
PAT-DX3 development path For personal use only • PAT-DX3 is differentiated from PAT-DX1 • Different pharmacokinetic profile • Crosses the blood brain barrier independent of cancer in the brain • Efficacy in animal models • Potential for use as a targeting agent (more conjugation sites than PAT-DX1)
Slide 18: Why Patrys? Why now?
Why Patrys? Why now? For personal use only Patrys’ deoxymab antibodies have a novel target and mechanism, and are effective in animal models of multiple cancer types Deoxymabs target indications with significant unmet medical – including triple negative breast cancer, primary and secondary brain can
Slide 19: Contact
For personal use only Contact Dr. James Campbell CEO and MD +61 3 9670 3273 info@patrys.com patrys.com Patrys Limited (ASX:PAB)
Patrys — ShareCafe Small Cap "Hidden Gems" Webinar (November 2022) on 6ix